Table 2 Multivariate analysis of LC3B globular structures and other clinical pathological parameters that may have a potential role in prognosis. The presence of LC3B globular structures has a strong independent prognostic value (p < 0.001)
From: LC3B globular structures correlate with survival in esophageal adenocarcinoma
Group 1 patients (neoadjuvant-naïve) | Group 2 (neoadjuvant therapy) | |||
|---|---|---|---|---|
Hazard ratio (95 % CI) | p-value | Hazard ratio (95 % CI) | p-value | |
LC3B globular structures | ||||
Negative v’s Positive | 6.086 (3.179–11.653) | <0.001* | 9.136 (2.115–39.462) | 0.003* |
Differentiation | ||||
Mild* | 1(−) | 0 | 1(−) | 0 |
Moderate | 0.667 (0.213–2.086) | 0.487 | 0.000 | 0.976 |
Poor | 0.898 (0.516–1.564) | 0.704 | 0.677 (0.318–1.441) | 0.311 |
Tumor staging | ||||
Stage I* | 1(−) | 0 | 1(−) | 0 |
Stage II | 0.627 (0.193–2.029) | 0.435 | 2.877 (0.323–25.59) | 0.343 |
Stage III-IV | 0.858 (0.204–3.608) | 0.835 | 5.043 (0.457–55.67) | 0.187 |
Lymphatic mets | ||||
Negative v’s Positive | 1.632 (0.504–5.288) | 0.414 | 0.634 (0.196–2.055) | 0.448 |
Vascular invasion | ||||
Negative v’s Positive | 2.304 (1.211–4.384) | 0.011* | 0.559 (0.220–1.416) | 0.220 |
Neural invasion | ||||
Negative v’s Positive | 1.050 (0.548–2.009) | 0.883 | 2.327 (0.876–6.181) | 0.090 |